Hepatitis E Diagnostic Tests Market: Global Industry Analysis and Forecast (2023-2032) by Test Type, End-Users, and Region

Global Hepatitis E Diagnostics Market: Description
The Hepatitis E virus (HEV) is the world’s leading cause of acute viral hepatitis, primarily affecting the liver. The HEV is classified as a travel-related infection.
A lack of basic sanitation and frequent cases of water contamination are major sources of hepatitis E infections.
It can be caused by a drug overdose, alcoholism, or autoimmune hepatitis. Hepatitis is commonly linked with fatigue, black urine, abdominal pain, and loss of appetite.
There is no specific treatment for hepatitis E. Analysis of HEV are performed on RNA in biologic specimens such as liver biopsy, stools, and serums, which fuels the demand for diagnostic tests for hepatitis E, especially among individuals between 15 and 40 years.
The most significant ways of hepatitis virus prevention are good personal cleanliness, safe public water supply, efficient sanitary waste disposal, and food safety.

Global Hepatitis E Diagnostics Market: Overview
The Global Hepatitis E Diagnostics Market is valued at US $ 79.08 Billion in 2030, growing at a CAGR of 4.5%.
The global market for hepatitis E diagnostic tests is expanding as the prevalence of hepatitis E rises, particularly in resource-poor nations.
Furthermore, the rise in scarcity of drinkable water, poor nutrition, and the increase in tourism are expected to drive growth in the global hepatitis E diagnostic tests market.
Various governments and healthcare authorities are taking the initiative and supporting hospitals and clinics to make diagnostic tests available in the nations, which is expected to drive the global hepatitis E diagnostic testing market.

Key Trends of Global Hepatitis E Diagnostics Market
Rise in the Incidences of Hepatitis E Globally
The global hepatitis e diagnostic tests market is being propelled by rising public awareness about the need of early HEV detection. IgG titers in the sample set imply that the person has been infected with HEV earlier. In the hepatitis E diagnostic tests market, research institutions and diagnostic laboratories are likely to see significant expansion.

The rising seroprevalence of hepatitis E, which was formerly thought to be a silent illness, has prompted further research into the disease’s transmission mechanisms, resulting in the development of research institutions. In addition to that, research is being undertaken on the severe sequelae of hepatitis E, as well as the method of infection of distinct genotypes of hepatitis E, all of which contribute to research institutes’ revenue share in the global hepatitis e diagnostic test market.

Unfavourable reimbursement policies to Hamper Global Hepatitis E Diagnostic Tests Market
Product offering at relatively lower than average selling price has increased market penetration of local players having wide distribution network in certain geographies This is imposing pricing pressure on major manufacturers, thereby intensifying competition. Dominance of local players offering a wide range of reagents portfolio at lower rates is hampering the geographic expansion of major players in particular regions.

Segmental Analysis of Global Hepatitis E Diagnostics Market:
Based on Product
• ELISA HEV IgM Test Kits
• ELISA HEV IgM Test Kits
• RT-PCR Test Kits
• Others

Based on End-user
• Healthcare Institutions
• Diagnostics Laboratories
• Research Centers
• Point-of-Care

Geographical Analysis of Global Hepatitis E Diagnostics Market:
The Global Hepatitis E Diagnostics Market is further segmented into five major countries- North America, Europe, Asia-Pacific, Latin America and Middle East and Africa.
Asia Pacific was the dominant region in hepatitis E diagnostic tests market and is expected to remain dominant during the forecast period. Asia Pacific and Middle East and Africa, accounted for a combined market share of more than 60%.
North America, and Europe which are the developed regions, do not have significant prevalence of hepatitis E, as this disease is found to be more prevalent in the regions with poor sanitation facilities and with lack of safe drinking water.

Regions Covered
• North America (US, Canada)
• Europe (UK, Germany, Spain, Italy, France)
• Asia-Pacific (India, China, Japan, Australia, South Korea)
• Latin America (Mexico, Brazil, Argentina)
• Middle East and Africa (UAE, Saudi Arabia, South Africa, Egypt)

Major players profiledBiomerieux, Roche Diagnostics, Fortress Diagnostics, Abbexa, Dia.Pro Diagnostics Bioprobes Srl, Wantai BioPharm, Mikrogen Diagnostics, ELITech Group, MP Biomedicals, and Siemens Healthineers.